Effect of Resistance and Aerobic Exercise in CIDP or MMN
- Conditions
- Chronic Inflammatory Demyelinating PolyneuropathyMultifocal Motor Neuropathy
- Interventions
- Other: Resistance trainingOther: Aerobic training
- Registration Number
- NCT02121678
- Lead Sponsor
- University of Aarhus
- Brief Summary
Resistance and aerobic exercise has been shown to be effective for maintenance of muscle strength in patients with neuromuscular diseases.
Exercise in CIDP and MMN is sparsely described. The aim of the study is to evaluate changes in muscle strength during high intensive resistance training and changes in maximal oxygen consumption (VO2-max) during high intensive aerobic training in patients with CIDP or MMN in maintenance therapy with subcutaneous immunoglobulin.
The hypotheses are that muscle strength and VO2-max are significantly increased during the training sessions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
- Age > 18 and < 80 years
- Diagnosed with definite or probable CIDP or definite or probable MMN fulfilling the European Federation of Neurological Sciences/Peripheral Nerve Society (EFNS/PNS) criteria
- Stable maintenance therapy with immunoglobulin (no change of dosage < 3 months before inclusion)
- Duration of CIDP or MMN > 6 months
- Negative result on a pregnancy test (HCG-based assay in urine) for women of childbearing potential and use of a reliable method of contraception for the duration of the study
- Other cause of neuropathy (incl. pressure neuropathy)
- Exercise before enrolment (> 1 hour of exercise per week or > 4 km bicycling per day)
- Walking distance < 10 meter with or without aid
- Diabetes mellitus, severe cardiac or pulmonary disease, malignancies
- Known history of adverse reactions to Immunoglobulin A in other products
- Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products.
- History of malignancies of lymphoid cells and immunodeficiency with lymphoma
- Known liver function impairment (ALAT 3 times above upper limit of normal)
- Known protein-losing enteropathies or proteinuria.
- Known of renal function impairment (creatinine >120 micromol/L or creatinine >1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
- Treatment with any investigational medicinal product within 3 months prior to first infusion of Gammanorm
- Known or suspected HIV, Hepatitis Virus C or B infection
- Pregnant or nursing women
- Planned pregnancy during course of the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Run-in - Aerobic - Resistance Resistance training * Week -12 to 0: Run-in period with no training * Week 0 to 12: Aerobic training on ergometer bicycle * Week 12 to 24: Resistance training with dumbbells Run-in - Resistance - Aerobic Aerobic training * Week -12 to 0: Run-in period with no training * Week 0 to 12: Resistance training with dumbbells * Week 12 to 24: Aerobic training on ergometer bicycle Run-in - Aerobic - Resistance Aerobic training * Week -12 to 0: Run-in period with no training * Week 0 to 12: Aerobic training on ergometer bicycle * Week 12 to 24: Resistance training with dumbbells Run-in - Resistance - Aerobic Resistance training * Week -12 to 0: Run-in period with no training * Week 0 to 12: Resistance training with dumbbells * Week 12 to 24: Aerobic training on ergometer bicycle
- Primary Outcome Measures
Name Time Method Changes in maximal oxygen consumption (VO2-max) -12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks VO2-max are measured during the 12 weeks aerobic exercise session and at enrolment 12 weeks before start of exercise.
VO2-max are measured while the participant running on a ergometer bicycle by accumulation of exhaled airChanges in isokinetic muscle strength -12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks Changes in isokinetic muscle strength during resistance exercise. Four muscle groups bilateral are selected.
CIDP: Knee flexion/extension Elbow flexion/extension MMN: Elbow flexion/extension Wrist flexion/extension
- Secondary Outcome Measures
Name Time Method Change in Overall Disability Sum Score (ODSS) -12, 0, 6, 12, 18, 24 weeks Change in Medical Research Council (MRC) -12, 0, 6, 12, 18, 24 weeks Change in Quality of Life measured by The Short Form (36) Health Survey (SF-36) questionnaire -12, 0, 6, 12, 18, 24 weeks Change in 6-Minute Walk test -12, 0, 6, 12 weeks or -12, 0, 12, 18, 24 weeks Change in Fatigue Severity Score (FSS) -12, 0, 6, 12, 18, 24 weeks
Trial Locations
- Locations (2)
Department of Neurology, Aarhus University Hospital
🇩🇰Aarhus C, Denmark
Department of Neurology, Rigshospitalet, Copenhagen University Hospital
🇩🇰Copenhagen, Denmark